PDT Partners LLC Makes New Investment in Smith & Nephew SNATS, Inc. $SNN

PDT Partners LLC bought a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 67,780 shares of the medical equipment provider’s stock, valued at approximately $4,251,000.

Several other institutional investors have also recently made changes to their positions in SNN. BlackRock Inc. purchased a new stake in Smith & Nephew SNATS in the second quarter worth about $505,323,000. River Road Asset Management LLC raised its holdings in shares of Smith & Nephew SNATS by 13.8% in the 4th quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock valued at $103,996,000 after purchasing an additional 384,926 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Smith & Nephew SNATS by 5.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock valued at $67,383,000 after purchasing an additional 100,697 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Smith & Nephew SNATS in the 2nd quarter worth approximately $89,325,000. Finally, Dimensional Fund Advisors LP increased its holdings in Smith & Nephew SNATS by 44.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,052,747 shares of the medical equipment provider’s stock valued at $33,436,000 after buying an additional 324,080 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on SNN. Kepler Capital Markets downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew SNATS in a report on Thursday, August 6th. Canaccord Genuity Group lowered their price target on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a report on Monday, May 11th. Barclays downgraded shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings lowered shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Trading Down 1.4%

Shares of Smith & Nephew SNATS stock opened at $29.21 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. Smith & Nephew SNATS, Inc. has a 12-month low of $28.56 and a 12-month high of $38.79. The firm’s 50 day simple moving average is $30.28 and its two-hundred day simple moving average is $31.78.

Smith & Nephew SNATS Announces Dividend

The business also recently disclosed a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be issued a dividend of $0.312 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a dividend yield of 205.0%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.